About
ImmunoBrain Checkpoint (IBC) is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. IBC’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. IBC's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.
Tags
Total Employees
14
Current headcount
Score Breakdown
35Traction
12Team
30Visibility
26Profile
70Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does ImmunoBrain Checkpoint do?
ImmunoBrain Checkpoint (IBC) is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. IBC’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. IBC's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific d…
When was ImmunoBrain Checkpoint founded?
ImmunoBrain Checkpoint was founded in 2016.
What industry does ImmunoBrain Checkpoint operate in?
ImmunoBrain Checkpoint operates in Healthcare, Immunology, Immunotherapy, Alzheimers, Neurology, Biopharmaceutical.
How many employees does ImmunoBrain Checkpoint have?
ImmunoBrain Checkpoint has approximately 14 people on record.